Mast Therapeutics (SVRA) Earns Daily News Sentiment Score of 0.07

Media stories about Mast Therapeutics (NASDAQ:SVRA) have been trending somewhat positive on Tuesday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mast Therapeutics earned a news impact score of 0.07 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.8371326786222 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news headlines that may have effected Accern’s scoring:

Shares of Mast Therapeutics (SVRA) traded down $0.44 during trading on Tuesday, hitting $13.05. The stock had a trading volume of 132,800 shares, compared to its average volume of 113,891. The company has a quick ratio of 9.15, a current ratio of 9.15 and a debt-to-equity ratio of 0.20. Mast Therapeutics has a 52-week low of $4.60 and a 52-week high of $16.10.

A number of research analysts have commented on SVRA shares. ValuEngine lowered Mast Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday. Zacks Investment Research cut Mast Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, November 23rd. Roth Capital lowered their price target on Mast Therapeutics from $40.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, October 31st. Canaccord Genuity increased their price target on Mast Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a report on Monday, October 30th. Finally, Jefferies Group began coverage on Mast Therapeutics in a report on Friday, September 22nd. They issued a “buy” rating and a $20.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $21.30.

In related news, Director Yuri Pikover purchased 50,000 shares of the company’s stock in a transaction that occurred on Friday, October 27th. The stock was bought at an average price of $7.85 per share, for a total transaction of $392,500.00. Following the completion of the transaction, the director now owns 150,000 shares in the company, valued at approximately $1,177,500. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 6.93% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/12/05/mast-therapeutics-svra-getting-somewhat-favorable-press-coverage-report-shows.html.

About Mast Therapeutics

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Insider Buying and Selling by Quarter for Mast Therapeutics (NASDAQ:SVRA)

Receive News & Ratings for Mast Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply